Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study by Nielsen, L.K. et al.
1650 haematologica | 2020; 105(6)
Received: April 19, 2019.
Accepted: September 11, 2019.
Pre-published: September 12, 2019.
©2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-







ARTICLE Plasma Cell Disorders
doi:10.3324/haematol.2019.222299
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/105/6/1650
Ferrata Storti Foundation
Data on the impact of long term treatment with immunomodulatorydrugs (IMiD) on health-related quality of life (HRQoL) is limited.The HOVON-87/NMSG18 study was a randomized, phase 3 study
in newly diagnosed transplant ineligible patients with multiple myeloma,
comparing melphalan-prednisolone in combination with thalidomide or
lenalidomide, followed by maintenance therapy until progression (MPT-T
or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were com-
pleted at baseline, after three and nine induction cycles and six and 12
months of maintenance therapy. Linear mixed models and minimal impor-
tant differences were used for evaluation. 596 patients participated in
HRQoL reporting. Patients reported clinically relevant improvement in
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ABSTRACT
global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain
in both arms. The latter being of large effect size. In general, improvement occurred after 6-12 months of
maintenance only and was independent of the World Health Organisation performance at baseline. Patients
treated with MPR-R reported clinically relevant worsening of diarrhea, and patients treated with MPT-T
reported a higher incidence of neuropathy. Patients who remained on lenalidomide maintenance therapy for
at least  three months reported clinically meaningful improvement in global QoL and role functioning at six
months, remaining stable thereafter. There were no clinically meaningful deteriorations, but patients on
thalidomide reported clinically relevant worsening in neuropathy.  In general, HRQoL improves both during
induction and maintenance therapy with immunomodulatory drugs. The side effect profile of treatment did
not negatively affect global QoL, but it was, however, clinically relevant for the patients. (Clinicaltrials.gov
identifier: NTR1630) .  
HRQoL with thalidomide and lenalidomide
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Introduction
Multiple myeloma (MM) is a malignancy of the plasma
cells in the bone marrow. Patients with MM are at high
risk of developing bone destructions and fractures, hyper-
calcaemia, renal failure and anemia.1,2 Compared to
patients with other hematological malignancies, patients
with MM report a higher incidence and severity of symp-
toms with a reduced health-related quality of life
(HRQoL) as a consequence.3-5 However, there is limited
data on the effect of first line treatment on HRQoL in
transplant ineligible, newly diagnosed patients with MM
(NDMM), especially throughout maintenance treatment.6
In several of these trials, the immunomodulatory drugs
(IMiDs) thalidomide and/or lenalidomide were investigat-
ed.7-13 HRQoL during treatment with thalidomide and
lenalidomide were compared head to head in the FIRST
and the ECOG E1A06 trials only.10,14 
The FIRST trial compared continuous therapy with
lenalidomide and dexamethasone (Rd), with Rd for 18
months, and melphalan-prednisone-thalidomide (MPT)
for 18 months.14 Clinically relevant changes were pub-
lished only for six HRQoL scales.9 These were preselected
as they were perceived to be clinically relevant. Both Rd
and MPT resulted in a statistically significant improve-
ment in all subscales, except side effects of treatment that
worsened over time in both arms. There were no differ-
ences between arms in global quality of life (QoL), physi-
cal functioning, pain and fatigue; although Rd treated
patients reported significantly less side effects of treat-
ment and less disease symptoms at three months com-
pared to MPT. A post hoc prediction model was developed,
suggesting that HRQoL was at least maintained or further
improved beyond 18 months. Unfortunately, the effect of
Rd continuous versus 18 months only on HRQoL cannot
be deduced with certainty from this study, as HRQoL data
beyond 18 months was lacking.13
In contrast to the FIRST trial, in the ECOG E1A06 trial,
the Functional Assessment of Cancer Therapy-
Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) score
was used for HRQoL evaluation, instead of the European
Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30. It was shown that melphalan-pred-
nisone-lenalidomide (MPR) followed by lenalidomide
maintenance (MPR-R) resulted in a superior HRQoL after
12 months only, compared to MPT followed by thalido-
mide maintenance (MPT-T).10 However, the HRQoL
effects of lenalidomide and thalidomide maintenance ther-
apies were not investigated separately. 
The effect of MPR-R on HRQoL might be deduced
from the MM-015 trial, comparing MPR-R, MPR and mel-
phalan-prednisolone (MP).11,15 After six months of mainte-
nance, patients who actually received MPR-R therapy
reported a statistically significant improvement in
HRQoL in 5 of 6 subscales, versus in 2 of 6 subscales only
in MP and MPR treated patients. However, also from this
study, HRQoL data beyond six months of maintenance
therapy is lacking.6,11 
Recently, the data from the MRC IX study showed that
maintenance therapy with thalidomide resulted in an
inferior global QoL after three months with a persistent
trend for detriment at six and 12 months.12 This is impor-
tant as, especially after achieving disease control with
induction therapy, long-term continuation of mainte-
nance therapy may turn the pros of maintenance therapy
into cons because of side effects that negatively affect
HRQoL. The data on lenalidomide maintenance therapy,
however, is limited.10,11,13,16 Data from a prospective obser-
vational cohort study showed no negative impact of
lenalidomide maintenance  therapy following autologous
stem cell transplantation.16 To the best of our knowledge,
prospective analyses after six months of maintenance
therapy in non-transplant eligible patients with NDMM
are lacking. Only the post hoc analysis of the FIRST trial is
available.13
We here report data on all the collected HRQoL sub-
scales from the open-label, randomized HOVON-
87/NMSG18 study, thereby providing HRQoL data, not
only during induction, but also during maintenance ther-
apy with lenalidomide and thalidomide therapy.17
Although currently both IMiD-based regimens are mainly
replaced by Rd continuously, either combined with borte-
zomib during induction or not, the impact of long term
lenalidomide on HRQoL is of interest. In addition, we
discuss methods to account for the impact of differences
in discontinuation rate due to toxicity between the two
arms on the outcome of HRQoL analysis.
Methods 
Study design
Study details have been published previously.17 In brief, symp-
tomatic patients with NDMM >65 years of age or transplant
ineligible patients ≤65 years were included. Patients were ran-
domized between nine 28-day induction cycles of MPT, fol-
lowed by thalidomide maintenance (MPT-T) or nine 28-day
induction cycles of MPR followed by lenalidomide maintenance
(MPR-R). Maintenance treatment was given until progression,
intolerable side effects or other conditions that required treat-
ment discontinuation. The study protocol was approved by the
Ethics Committee, and written informed consent was obtained
from all participants. The study was registered at www.trialregis-
ter.nl as NTR1630.
Health-related quality of life assessments
Participation in the HRQoL reporting was optional.
Questionnaires were given to the patients at baseline (T0), after
induction cycle 3 (T1) and  cycle 9 (T2), and after six (T3) and 12
(T4) months of maintenance therapy. 
For HRQoL assessment, two EORTC QoL questionnaires
were used; the QLQ-C30 and the Myeloma specific QLQ-
MY20.18,19 The QLQ-C30 contains five functional scales, nine
symptom scales and one global QoL scale.20,21 The QLQ-MY20
contains two functional and two symptom scales. For the evalu-
ation of peripheral neuropathy, question 13 of the QLQ-MY20
“Did you have tingling hands or feet?” was used. The EORTC man-
ual21 was used to calculate all HRQoL scales. A detailed descrip-
tion of the questionnaires and neuropathy scale, data collection
and assignment of the questionnaires to T0-T4 is found in the
Online Supplementary Material and Methods.
Statistical analyses
Change in HRQoL over time was assessed by linear mixed
models, both “within arms” and “between arms”, from T0 to T4,
as well as from T2 to T4 for patients who had at least three
months of maintenance therapy. A P-value <0.005 was consid-
ered statistically significant as multiple subscales were tested.
Model estimates were used for post hoc comparisons of changes
from baseline.21 A change in mean HRQoL score was defined as
clinically meaningful if it was above the minimal important dif-
ference (MID) threshold using distribution-based MID calculat-
ed for both QLQ-C30 and MY20 subscales.22 MID between arms
was defined as >5 points difference at a specific time point.22 For
QLQ-C30 subscales, an additional anchor-based method by
Cocks was used, assessing whether HRQoL changes and differ-
ences were of small, medium or large effect.23,24 Details are
described in the Online Supplementary Material and Methods.
To check for effect modification by the World Health
Organisation (WHO) performance, sex, age and treatment
response, linear mixed models included fixed effects for time,
WHO, sex, age, treatment response and their two-way interac-
tion and a random slope for subject.
HRQoL questionnaires were not systematically collected from
patients who discontinued treatment, which might introduce a
bias when comparing HRQoL. Therefore, we investigated the
impact of missing data due to treatment discontinuation on
changes in HRQoL over time. We compared HRQoL of i)
patients on and off protocol matched by timing, ii) patients who
discontinued therapy before or after start of maintenance, and
iii) patients who discontinued therapy because of peripheral
neuropathy versus patients still on protocol until 12 months
maintenance therapy. For a detailed description, see the Online
Supplementary Appendix Materials and Methods. 
For statistical analysis, SPSS version 22.0 was used. 
Results
Ninety-four percent (596) of the 637 patients included
in the HOVON-87/NSMG18 trial gave informed consent
for participation in the HRQoL study. Only patients who
filled out a baseline questionnaire were included in the
HRQoL analysis; 272 patients in MPT-T versus 281
patients in MPR-R. The patient- and disease characteris-
tics of the HRQoL cohort (Table 1) were comparable to
the original study population.17 The patient flow and
drop-out during study are presented in the CONSORT
diagram in Figure 1. Fewer patients in the MPT-T arm
started maintenance compared to patients in the MPR-R
arm, 146 (54%) versus 174 (62%). In addition, more
patients discontinued MPT-T than MPR-R (first year dis-
continuation rate; 68% vs. 30%; P<0.001). The main rea-
son for discontinuation was peripheral neuropathy for
thalidomide and hematological toxicity for lenalido-
mide.17 A graphic presentation of the number of patients
on protocol and the number of completed questionnaires
at each scheduled time point, ranging from 69-87%, is
presented in the Online Supplementary Figure S1. At base-
line, no significant differences existed between the treat-
ment arms (Online Supplementary Table S1).
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Table 1. Demographic characteristics of the patients included in the
health-related quality of life analysis.
Demographic characteristics                           MPT-T               MPR-R
                                                                       (N=272)            (N=281)
Median age, years (IQR)                                       72 (69-77)           73 (69-77)
Age ≥ 76 years, N (%)                                           90 (33%)             98 (35%)
Sex, N (%)                                                                                                        
Male                                                                          133 (49%)           164 (58%)
Female                                                                     139 (51%)           117 (42%)
WHO performance, N (%)                                                                            
0                                                                                  89 (33%)            107 (38%)
1                                                                                 132 (49%)           124 (44%)
2                                                                                  39 (14%)             40 (14%)
3                                                                                    5 (2%)                  5 (2%)
Unknown                                                                    6 (2%)                  5 (2%)
M-protein subtype, N (%)                                                                            
IgG                                                                            177 (65%)           176 (63%)
IgA                                                                              73 (27%)             69 (25%)
IgD                                                                               4 (2%)              1 (<0.5%)
Light chain only                                                        17 (6%)               34 (12%)
Unknown                                                                    0 (0%)              1 (<0.5%)
ISS, N (%)                                                                                                         
I                                                                                  61 (23%)             78 (28%)
II                                                                                134 (49%)           136 (48%)
III                                                                               74 (27%)             65 (23%)
Unknown/missing                                                     3 (1%)                  2 (1%)
Lytic bone lesions, N (%)                                                                             
None                                                                          86 (32%)             89 (32%)
1                                                                                   25 (9%)                19 (7%)
2                                                                                   15 (6%)                19 (7%)
3 or more                                                                141 (52%)           150 (53%)
Unknown/missing                                                     5 (2%)                  4 (1%)
FISH performed, N (%)                                                                                
Yes                                                                            206 (76%)           220 (78%)
FISH abnormality if performed, N (%)                                                      
17p13 loss                                                             23/188 (12%)       16/196 (8%)
t(4;14)(p16;q32)                                                  18/199 (9%)        17/216 (8%)
t(14;16)(q32;q23)                                                 2/170 (1%)         10/192 (5%)
1q21 gain                                                               56/146 (38%)     58/165 (35%)
MPT-T: melphalan-prednisone-thalidomide induction and thalidomide maintenance
therapy; MPR-R: melphalan-prednisone-lenalidomide induction and lenalidomide
maintenance therapy; n: number of patients; IQR: interquartile range, WHO: World
Health Organisation; ISS: International Staging System; FISH: fluorescence in situ
hybridization.
Percentage of patients reaching a clinically 
meaningful change in HRQoL 
In both arms, clinically relevant improvement in global
QoL was more prominent than deterioration (Figure 2).
During MPT induction therapy, improvement occurred in
48% of patients versus deterioration in 32%. With MPR
induction improvement was reported in 52% of patients
versus in 28% deterioration. After 1 year of thalidomide
maintenance, 54% of patients improved versus 32% dete-
riorated. For lenalidomide maintenance these figures were
61% versus 19%, respectively. The results for all other sub-
scales are presented in Figure 2. Clinically relevant deteri-
oration in peripheral neuropathy was significantly more
frequently reported in the patients treated with MPT-T
than in the patients treated with MPR-R, both after induc-
tion (55% vs. 27%; P<0.001) and after maintenance (63%
vs. 31%; P=0.003). A significantly higher percentage of
patients treated with MPR reported clinically relevant
worsening of diarrhea, compared to MPT, however after
induction only (31% vs. 9%; P<0.001).
Changes in HRQoL within each treatment arm during
induction and maintenance
In both arms, a significant improvement in HRQoL over
time was observed for the majority of scales, irrespective
of the received treatment. Global QoL, role and emotional
functioning, fatigue, pain, and future perspective
improved clinically relevant in both arms. In addition,
patients who were treated with thalidomide reported a
clinically relevant improvement in social functioning,
insomnia and appetite loss, while physical functioning
improved in patients who were treated with lenalidomide
(see Online Supplementary Table S2 for significant changes
over time; see Figure 3 and Online Supplementary Figure S2
for clinical meaningful changes within arms). Overall,
these HRQoL changes corresponded to medium clinical
effects, except for pain reduction, which corresponded to
a large clinical effect.24 In both arms, pain reduction was
observed, irrespective of the number of bone lesions (0 vs.
1-2 vs. ≥3) (Online Supplementary Figure S3). In general, clin-
ically meaningful improvement occurred from T3 and T4
onwards only (i.e. after six and 12 months of maintenance
therapy). In contrast, global QoL, future perspective and
pain improved already during induction therapy and was
sustained throughout the whole treatment (Figure 3 and
Online Supplementary Figure S2). Patients treated with
MPT-T reported a statistically significant, but not clinically
meaningful increase (small effect according to Cocks24) in
constipation and side effects of treatment (P=0.003 and
P<0.001 respectively, see Figure 3, Online Supplementary
HRQoL with thalidomide and lenalidomide
haematologica | 2020; 105(6) 1653
Figure 1. Consort diagram. Consort diagram of the number of patients participating in the health-related quality of life (HRQoL) study, the number of answered ques-
tionnaires and the number of patients off protocol and reason for treatment discontinuation.
Table S2 and Online Supplementary Figure S2). Patients
treated with MPR-R reported a statistically significant and
clinically meaningful increase (small effect according to
Cocks)24 in diarrhea (P<0.001, see Figure 3 and Online
Supplementary Table S2). Peripheral neuropathy worsened
in both arms (both P<0.001, see Online Supplementary Table
S2), being clinically meaningful in patients treated with
thalidomide only (Figure 3).
Clinically relevant differences between arms in HRQoL
course during induction and maintenance
During treatment, clinically meaningful differences
occurred between arms in 13 of 21 scales (Figure 3 and
Online Supplementary Figure S2). Patients treated with
MPT-T reported less diarrhea at all follow-up time points
(difference between arms was of medium clinical effect,
according to Cocks23), pain at T1, fatigue at T2, and insom-
nia and appetite loss at T1 and T4. MPR-R treated patients
reported better future perspective, physical and role func-
tioning at T4, better cognitive functioning at T1 and T4,
and body image at T3, compared to the patients treated
with MPT-T. In addition, patients treated with MPT-T
reported more side effects of treatment at T3 and T4 and
more constipation and peripheral neuropathy at all fol-
low-up time points. According to the definition of Cocks,
all the differences between the arms were of small clinical
effect at the largest, except where stated differently
(Online Supplementary Table S2).23 
Changes in HRQoL within and between treatment arms
during maintenance only
We performed an analysis of a subset of 242 patients
who started and continued maintenance treatment for at
least three months and of whom a T2 questionnaire was
available: 95 of 146 patients who started with thalidomide
maintenance therapy (65%) and 147 of 174 patients who
started with lenalidomide maintenance therapy (84%). At
the start of maintenance, there was already a significant
difference in HRQoL in constipation, side effects of treat-
ment and neuropathy (less in MPR treated patients) and
diarrhea (less in MPT treated patients) (Online
Supplementary Table S1). During maintenance treatment, a
statistically significant reduction in appetite loss was
reported in both arms (thalidomide P=0.003, lenalidomide
P<0.001). In addition, during lenalidomide maintenance, a
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Figure 2. Responders. The percentage of patients reaching a clinically relevant change in health-related quality of life (HRQoL), e.g. reaching the minimal important
difference (MID) threshold for within group change during the induction phase (T2) and induction and maintenance phase together (T4). A significant difference
between the arms with respect to the percentage of patients improving or deteriorating by more than the MID was observed for diarrhoea and peripheral neuropathy
at T2 and for peripheral neuropathy at T4. 
significant improvement was observed in global QoL
(P=0.003, clinically relevant at T3), physical- (P<0.001) and
role functioning (P<0.001, clinically relevant at T4), fatigue
(P<0.001) and dyspnea (P=0.004). In contrast, no signifi-
cant improvement occurred during thalidomide mainte-
nance. There was even statistically significant worsening
of peripheral neuropathy symptoms (P<0.001, clinically
relevant at both T3 and T4) (Online Supplementary Table S3
and Online Supplementary Figure S4). Between arms, there
were clinically meaningful differences in physical and role
functioning (better with lenalidomide), in appetite loss
(worse with lenalidomide) and in neuropathy (worse with
thalidomide) (Online Supplementary Table S4 and Online
Supplementary Figure S4). All differences in QLQ-C30
scales were of small effect size (of note for neuropathy, no
effect sizes are available).23 
Analyses to account for missing data due to different
discontinuation rates between arms
Because more patients in the thalidomide arm discon-
tinued treatment compared to the lenalidomide arm17,
HRQoL of patients on protocol in the thalidomide arm
HRQoL with thalidomide and lenalidomide
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Figure 3. Health-related quality of life change over time. Estimated change in
health-related quality of life (HRQoL) score from baseline with corresponding 95%
confidence intervals (CI) and P-values for the five scales with a statistically signifi-
cant difference in change over time between treatment arms. Time points with clin-
ically meaningful difference between arms (minimal important difference [MID] >5
points) are marked with *. The dotted horizontal line represents the calculated
threshold for minimal important difference, the black for melphalan-prednisone-
thalidomide induction and thalidomide maintenance therapy (MPT-T) and the blue
for the melphalan-prednisone-lenalidomide induction and lenalidomide mainte-
nance therapy (MPR-R) treatment. The green arrows indicate the direction of
improvement in functional scales or reduction in symptom scales. The red arrows





could have been overestimated and toxicities underesti-
mated. We performed additional analyses to exclude such
a potential bias. Although it was not required, a question-
naire was available after treatment discontinuation (“off
protocol” questionnaires) from 90 patients (53 MPT-T and
37 MPR-R), of which 84 could be matched with question-
naires from patients on protocol with comparable age,
WHO, disease status, treatment arm and period. The glob-
al QoL for patients on protocol was comparable to
patients off protocol (mean score 59.9 vs. 66.3 points,
respectively, P=0.043; Online Supplementary Table S5).
Secondly, in general, the HRQoL course did not differ
between patients who discontinued therapy early (≤T2,
e.g. during induction) and those who discontinued therapy
late or never (>T2, e.g. from start maintenance; Online
Supplementary Table S6 and Online Supplementary Figure
S6). Lastly, global QoL over time did not differ between
patients discontinuing treatment due to investigator-
reported peripheral neuropathy and patients continuing
treatment until 12 months of maintenance therapy
(P<0.001; Online Supplementary Table S7 and Online
Supplementary Figure S6). These analyses support the
absence of bias in our analyses.
Effect modification of HRQoL change by baseline WHO
performance, gender, age and treatment response 
Baseline WHO performance status appeared to be an
effect modifier of HRQoL change during treatment for 7
of 21 scales in MPT-T treated- and in 12 of 21 scales in
MPR-R treated patients (Figure 4 for global QoL and
Online Supplementary Table S8 and Online Supplementary
Figure S8 for other subscales). A low performance status
(WHO score ≥2) was associated with a statistically signif-
icant overall lower HRQoL at baseline (data not shown),
which became comparable to the HRQoL of patients with
baseline WHO performance status 0-1 during treatment
(Online Supplementary Table S8 and Online Supplementary
Figure S7). Sex, age (≤75 years vs. >75 years) and treatment
response (≥partial response vs. stable/progressive disease)
did not modify HRQoL course (data not shown). The only
exception was observed for patients treated with MPT-T
≤75 years of age, who experienced more peripheral neu-
ropathy during treatment compared to those >75 years
(Online Supplementary Table S9 and Online Supplementary
Figure S8). 
Patient- versus investigator-reported peripheral
neuropathy
Figure 5 shows the patient-reported peripheral neuropa-
thy, as described in the method section, in comparison to
the investigator-reported CTCAE score at the given time
point. After dichotomizing peripheral neuropathy to “no”
or “mild” peripheral neuropathy versus “moderate” or
“severe neuropathy”, the kappa between patient-reported
and investigator-reported peripheral neuropathy was 0.33
(95% CI: 0.29–0.36). In 213 of 1,599 (13.3%) evaluable
questionnaires a discordance was found between neu-
ropathy grades reported by the patients versus investiga-
tors. In 76% of the cases, the investigator interpreted the
grade of neuropathy lower than experienced by the
patient.
Discussion
IMiD-based first line treatment of elderly non-trans-
plant eligible patients with NDMM improves both pro-
gression free and overall survival.25-28 We here show that
patients also perceive clinically relevant HRQoL benefits
of induction therapy with thalidomide and lenalidomide
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Figure 4. Effect modification of global quality of life by World Health Organisation status. Mean global quality of life (QoL) course over time with corresponding 95%
confidence intervals (CI) for each time point for (A) melphalan-prednisone-thalidomide induction and thalidomide maintenance therapy (MPT-T) and (B) patients treat-
ed with melphalan-prednisone-lenalidomide induction and lenalidomide maintenance therapy (MPR-R), differentiated by baseline World health organisation (WHO)
performance status 0 versus 1 versus 2/3. The black curve represents patients with baseline WHO status 0, the blue curve the patients with WHO status 1 and the
pink curve the patients with WHO status 2/3. The green arrows indicate the direction of improvement in functional scales and reduction in symptom scales.
followed by maintenance therapy. Importantly, there was
a clinically relevant decrease in pain, defined as large by
Cocks et al., in both arms. Clinically meaningful diarrhea
developed in approximately 30% of patients during
lenalidomide treatment, being of medium clinical effect
and significantly higher than in patients treated with
thalidomide. Importantly, in patients who reached main-
tenance, there was no clinically relevant further deteriora-
tion of diarrhea during MPR-R therapy. In contrast, clini-
cally meaningful peripheral neuropathy developed in
approximately 60% of patients during thalidomide treat-
ment, being significantly higher than in lenalidomide-
treated patients, both during induction and maintenance. 
In general, the improvement in HRQoL subscales
reached clinical relevance after six and 12 months of main-
tenance therapy only, with the exception of global QoL,
future perspective and pain, which improved early during
induction therapy and sustained during treatment. A sub-
analysis of patients who started maintenance therapy and
were treated for at least three months, showed that
lenalidomide resulted in a clinically meaningful improve-
ment in global QoL and role functioning over time, with-
out any clinically meaningful deteriorations. In contrast,
there was no clinical benefit of thalidomide maintenance
treatment, only clinically relevant worsening of peripheral
neuropathy occurred. 
Importantly, patients with a poor WHO performance
status of ≥2 at baseline reached similar HRQoL during
treatment, compared to patients with a better WHO per-
formance status at baseline, irrespective of the treatment
arm. Although this could be explained by regression to the
mean, indicating that the most pronounced improvement
can be achieved in patients with the worst HRQoL, it is
reasonable to suppose that the performance status can be
negatively affected by the disease and therefore that treat-
ment also improves HRQoL of the physically most com-
promised patients. Therefore, treatment should not be
automatically withheld from those patients. 
Our findings are in line with previous data on HRQoL
describing improvement in QoL during treatment.6 In
addition, we provide data about HRQoL during up to 1
year maintenance therapy with lenalidomide and thalido-
mide, being rarely reported in the current literature.10-13,16 
In view of the continuous lenalidomide treatment
approaches, our data showing clinically meaningful
improvement of global QoL during maintenance therapy
is important for clinical practice. In the FIRST trial, no such
improvement was reported; the global QoL remained sta-
ble, which might have been attributed to the higher dose
of lenalidomide and the continuation of dexamethasone,
known to be associated with side effects that can hamper
QoL.9 In the MM-015 trial, a statistically significant, but
not clinically relevant deterioration in global QoL after six
months of maintenance therapy was observed.11 This can-
not be accounted for by a difference in the percentage of
patients starting maintenance, the dose of lenalidomide,
response rates or different QoL evaluation methods. The
fact that thalidomide maintenance has only limited impact
on global QoL is in line with the data of the HOVON 49
and the MRC IX data. The latter even show an inferior
global QoL at three months with a trend to further detri-
ment during maintenance treatment.8,12 
A limitation of our and HRQoL studies of patients with
MM in general, is the fact that firstly, long term data
reflect a subset of patients who tolerate remaining in treat-
ment. Secondly, we collected no data after discontinuation
of the study although such results would rather reflect the
outcome of subsequent therapies.29 Therefore, biases are
common, and comparisons between therapies with 
different toxicities and discontinuation rates are difficult.
Especially, as missing data are not missing at random
when related to toxicity and cannot be corrected for.30
Such  bias might be present in our sub-analyses of patients
starting maintenance therapy, showing benefit for patients
treated with lenalidomide only. Therefore, this can only
be concluded for those patients who did benefit from
MPR induction and were able to continue lenalidomide. In
addition, the low number of patients continuing thalido-
mide might be the cause of a lack of finding statistically
significant changes in their HRQoL during maintenance. 
Interestingly, the higher incidence of peripheral neu-
ropathy with thalidomide, both clinically meaningful to
patients and according to CTCAE reported by physicians,
did not translate into an inferior global QoL, neither in our
study nor the FIRST trial.9 Via several analyses, we exclud-
ed a bias in global QoL evaluation due to missing HRQoL
questionnaires from patients who discontinued treatment
because of peripheral neuropathy. The fact that peripheral
neuropathy did not negatively affect HRQoL was surpris-
ing. The opposite has been reported.31 Our observation
might be explained by response shift, which is a well-
known phenomenon in longitudinal QoL research. It
reflects the probability that a patient’s standards and val-
ues change over time.32 Patients with MM might adapt to
their worsening function and increased symptoms and
thereby not allow these aspects to affect their global
QoL.33 However, it cannot be excluded that the global
QoL scale of the EORTC QLQ-C30 questionnaire has lim-
itations in detecting the negative impact of toxicity on
HRQoL. This discussion was addressed in a meta-analysis
by Schuurhuizen and colleagues,34 who also reported sim-
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Figure 5. Patient- versus investigator-reported peripheral neuropathy. Patient-
reported peripheral neuropathy compared to investigator-reported peripheral
neuropaty assessed by National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE) version 3.0. The surface of the circles reflects the
absolute number of patients plus investigators.
ilar global QoL in experimental versus control arms in
patients with colorectal cancer, despite higher toxicity
rates in the former. The authors question whether the
global QoL assessment, using the very brief two-item
global QoL scale, has sufficient measurement precision to
detect a difference in global QoL over time. However, this
has been challenged by others stating that QoL is a com-
plex and multidimensional concept, not caused by side
effects only.35 Importantly, both those in favor and those
against the limitations of the global QoL scale indicate the
need for development for more sensitive patient-reported
QoL instruments.36 This is also supported by our data on
peripheral neuropathy. We defined ‘tingling’ of hands or
feet as peripheral neuropathy. Although this approach is
not validated, we found a discrepancy between patient
and physician-reported neuropathy in 13% of question-
naires, the majority (76%) being explained by lower
reporting by physicians, which has been reported previ-
ously, both for neuropathy and other symptoms.37-39 The
use of the EORTC QLQ-CIPN20 questionnaire might
improve concordance between patients and physicians.40
The need for flexible and tailored patient reported out-
come (PRO) measurements has recently also been advo-
cated by Thanarajasingam and colleagues and these have
been developed by the EORTC.36,41 Furthermore, the PRO
version of the Common Terminologies Criteria for
Adverse Events (PRO-CTCAE) for self-reported toxicities
developed by the National Institute of Health is another
valuable tool.42,43 
In conclusion, we found that the treatment with MPT-T
and MPR-R improved HRQoL in elderly patients with
NDMM and in general is clinically meaningful to the
patients during maintenance therapy only. This supports
the current paradigm of continuous treatment, not only
improving survival, but also maintaining, and even
improving, specific subscales of HRQoL. Although clini-
cally relevant diarrhea developed in patients treated with
lenalidomide, this did not negatively affect the global QoL
during induction and maintenance. Moreover, currently it
is known that bile acid malabsorption plays an important
role, which can be treated with bile acid sequestrants.44
Clinically significant peripheral neuropathy precluded
long term thalidomide treatment in the majority of
patients and appeared not to improve HRQoL in those
patients who continued therapy. 
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